Boston Scientific to buy Nalu Medical for $533M

Boston Scientific said it will pay $533 million to buy the remaining equity in Nalu Medical, Inc., maker of a treatment for chronic peripheral nerve pain, as it continues its strategy of tuck-in acquisitions. https://lnkd.in/gQWtVWww

Boston Scientific said Friday it agreed to buy Nalu Medical, maker of a treatment for chronic peripheral nerve pain, to expand its neuromodulation portfolio. The company, which has been an investor in Nalu since 2017, said it will pay $533 million for the remaining equity that it does not already own. The purchase values Nalu at $600 million in total. Analysts said the transaction continues Boston Scientific’s strategy of expansion through tuck-in deals. “The acquisition fits Boston Scientific’s strategy of bringing in private investments to expand the portfolio,” Citi Research analyst Joanne Wuensch said in a note Friday. https://lnkd.in/gVZhsJv2

Blackstone and TPG are in advanced talks to acquire medical device maker Hologic for over $17 billion, potentially becoming one of 2025's largest private equity deals. https://lnkd.in/dyZuQWkV

Closing in on $2 billion in major deals this year, Boston Scientific Corp. moved to acquire the balance of Nalu Medical, Inc. it didn’t already own in a $533 million cash deal, expanding its chronic pain portfolio with the addition of peripheral nerve stimulation. The Nalu neurostimulation system delivers mild electrical impulses to interrupt aberrant pain signals from nerves in the shoulder, knee and lower back before they reach the brain. As part of Boston Scientific’s strategy to dominate the markets in which it plays via high-quality tuck-in M&A, the med-tech leader has executed more than 40 acquisitions in the past decade and maintains about 45 active venture investments. Major deals for the Marlborough, Mass.-based company this year include the up to $600 million acquisition of Sonovie Ltd., which closed in May, the $664 million purchase of Bolt Medical Inc. completed in April, and the $88 million acquisition of the bioenvelope business from Elutia Inc. announced in late September. Boston Scientific had existing stakes in all three companies. Read why Nalu attracted Boston Scientific’s interest and what’s next for the companies in Annette Marie Boyle’s article in BioWorld News. #medtech #chronicpain #neuromodulation https://lnkd.in/eZAuFkEq

Boston Scientific continues its acquisition streak, with the Nalu buy adding on to the $600 million acquisition of Sonovie Ltd., which closed in May, the $664 million purchase of Bolt Medical Inc. completed in April, and the $88 million acquisition of the bioenvelope business from Elutia Inc. announced in late September.  This latest acquisition complements Boston Scientific’s interventional pain portfolio, which currently includes spinal cord stimulation, basivertebral nerve ablation and radiofrequency ablation. Thank to Annette Marie Boyle for this great article.

𝐁𝐢𝐠𝐠𝐞𝐬𝐭 𝐌𝐞𝐝𝐓𝐞𝐜𝐡 𝐃𝐞𝐚𝐥𝐬 – 𝐀𝐝𝐣𝐮𝐬𝐭𝐞𝐝 𝐟𝐨𝐫 𝐈𝐧𝐟𝐥𝐚𝐭𝐢𝐨𝐧 I recently wrote about the biggest deals in the ,#Pharma industry over the years. Here is also a look at the biggest deals in the ,#MedTech industry. The following are some of the biggest MedTech deals based on their present value: 🔹Medtronic's acquisition of Covidien (Medtronic Minimally Invasive Therapies Group) 🔹Boston Scientific's acquisition of 𝐆𝐮𝐢𝐝𝐚𝐧𝐭 🔹Abbott's acquisition of St. Jude Medical 🔹BD's acquisition of CR Bard 🔹Johnson & Johnson's acquisition of Synthes (was merged with existing DePuy DePuy Synthes) 🔹Siemens Healthineers's acquisition of Varian I will write more about some of these acquisitions in my coming posts. * Views and ideas are my own. The content I provide here is all public data intended to be educational only and is not financial advice. I encourage the readers to do their research #MedTech #MedicalDevices #Q22025 #HealthcareInnovation #MarketLeaders #SurgicalRobotics #InfographicDesign #VisualStorytelling #MedicalTechnology #LinkedInInsights #ABOKHATWAVisuals #DataDrivenDesign #CinematicInfographics

MEDTECH SCOOP: Buyout firms Blackstone and TPG are closing in on a deal to acquire Hologic, Inc. in what would be one of the largest private equity takeovers this year. Blackstone and TPG are discussing a transaction that values Hologic at more than $17 billion including debt. It could be announced as soon as next week, assuming no last-minute snags. Hologic is focused on women’s health, and develops diagnostic solutions for breast and cervical cancer, as well as infectious diseases like Covid-19. Story for Bloomberg News with Michelle Davis and David Carnevali: https://t.co/uqjxRa2R0T

💡 AI-powered MedTech is driving a new wave of M&A in North America 2025 is shaping up to be a record year for MedTech mergers and acquisitions, with AI-driven medical device and diagnostics companies emerging as top targets Recent examples include: B. Braun’s acquisition of True Digital Surgery, expanding its surgical visualization capabilities GE HealthCare’s purchase of Icometrix, a neuro-AI company specializing in brain MRI analytics Analysts predict that consolidation will continue as large healthcare technology players seek AI expertise, data integration, and precision diagnostics to strengthen their portfolios This M&A momentum signals a broader trend — the fusion of AI and medical devices is no longer the future; it’s the competitive edge of today’s MedTech industry #MedTech #AIinHealthcare #MergersAndAcquisitions #HealthcareInnovation #DigitalHealth #MedicalDevices #FutureOfMedicine https://lnkd.in/gBpZKvYp

MEETING REPORTER Eyecelerator: What drives real value in ophthalmic innovation and acquisition? During this dynamic panel moderated by Drs. Robert Avery and Rajesh Rajpal, leaders from Alcon, Ocular Therapeutix, Leerink Partners, EyeBio (Merck), Roche,and Astellas shared firsthand perspectives on how to navigate the complex journey from startup innovation to strategic acquisition. Key Takeaway Pearls: 1. Build to go long. Successful exits often come to companies designed to reach approval and commercialization—not those built solely for sale. A solid, independent growth plan increases both leverage and valuation. 2. Relationships drive deals. M&A in ophthalmology isn’t an auction—it’s a relationship game. Cultivate trust with potential acquirers years in advance; most large deals evolve from longstanding engagement, not quick negotiations. 3. Timing is everything. Offers that come too early—or before key data readouts—can hinder long-term value. Companies should have their “house in order” (board, data, legal, alignment) so they can move quickly when the timing is right. 4. Data wins. Decision-making must be driven by strong, clean, reproducible data. Strategics emphasized that clarity in the science and development plan is the foundation of any deal conversation. 5. Strategic fit matters. Corporates like Alcon, Roche, and Astellas look for alignment in three areas: cutting-edge science, complementary capabilities, and cultural fit. Early, open dialogue helps ensure both sides share a common vision. 6. Bankers add value—at the right moment. Investment bankers can help maximize outcomes once a serious offer or term sheet is on the table. However, premature formal involvement can disrupt early, collegial relationship-building with strategics. 7. Capital strength equals leverage. Companies that raise capital prior to acquisition tend to command stronger valuations—showing the ability to “go it alone” if needed. The consensus: the ophthalmic ecosystem has never been stronger. Innovation is thriving, collaboration is key, and those who combine vision, timing, and trusted relationships are best positioned to create lasting value. #Ophthalmology #Innovation #Biotech #MedTech #MergersAndAcquisitions #Leadership #Investing #EyeCare #LifeSciences #aao #escrs #ascrs

Strategic Pathways: Driving Value Through Ophthalmic Innovation and Acquisition: Robert L. Avery, MD, Rajesh K. Rajpal, MD, Laurent Attias, Pravin U. Dugel, Andrew Gitkin, David R. Guyer, MD, Esther Melo, PhD, Peter Sandor, MD Alcon, Ocular Therapeutix, Inc., Leerink Partners, EyeBio, Roche Pharma Astellas Pharma https://lnkd.in/eeW6uPVh